Clinical Trials Logo
  1. Home
  2. Urinary Bladder Cancer
  3. NCT06156787
  4. Details
NCT06156787 Clinical Trial

Patterns of Urinary Bladder Cancer in Darfur, Suda

Urinary Bladder Cancer Clinical Trial

Official title:
Patterns of Urinary Bladder Cancer in Darfur, Sudan 2020 - 2022

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT06156787
Other study ID # ElbagieaBladder
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 1, 2020
Est. completion date April 10, 2022

Study information
Verified date November 2023
Source National Center for Gastroentestinal and Liver Disease
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: Bladder cancer (BC) exhibits extreme heterogeneity regarding clinical outcome, etiology, histology, and geographic distribution. Recent clinical observations point to alterations in the BC pattern in the Sudan, possibly as a result of lifestyle changes brought on by the enormous migration from rural to urban locations. This study aimed to identify the pattern of bladder cancer in Darfur. Patients and Methods: A cross sectional, hospital-based study, it was conducted inNyala specialized hospital, during the period from (2020 to 2022), included one hundred and five patients with bladder mass matching the inclusion criteria were studied over the diversity of demographic data , clinical finding, pathological type and possible risk factors .

Recruitment information / eligibility
Status Completed
Enrollment 105
Est. completion date April 10, 2022
Est. primary completion date April 1, 2022
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All Sudanese pts who lives in Darfur and presented with urinary bladder mass. - Adult above 18 years Exclusion Criteria: - Patient who does not live in Darfur. - Patients refused to participate in the study.

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Sudan Nyala specialized hospital Darfur

Sponsors (1)
Lead Sponsor Collaborator
National Center for Gastroentestinal and Liver Disease

Country where clinical trial is conducted

Sudan, 

Outcome
Type Measure Description Time frame Safety issue
Primary Patterns of Urinary Bladder Cancer in Darfur, Sudan This research study investigates the patterns of urinary bladder cancer (BC) in Darfur, Sudan, with a focus on understanding the clinical outcomes, etiology, histology, and demographic distribution of the disease. The research is a cross-sectional, hospital-based study conducted at Nyala Specialized Hospital in Darfur. The study spans a period from 2020 to 2022.
See also
  Status Clinical Trial Phase
Recruiting NCT00872495 - Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
Withdrawn NCT05335707 - Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy
Completed NCT03998579 - Physical Rehabilitation Among Patients Undergoing Radical Cystectomy Due to Urinary Bladder Cancer N/A
Not yet recruiting NCT04525781 - Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder Cancer
Completed NCT02897765 - A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer Phase 1
Recruiting NCT05822934 - Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer Phase 3
Completed NCT02722538 - Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer Phase 1
Completed NCT02437539 - Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography Phase 1
Completed NCT02139371 - Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography Phase 0
Completed NCT03433924 - An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.
Active, not recruiting NCT03132922 - MAGE-A4ᶜ¹º³²T for Multi-Tumor Phase 1
Completed NCT05946369 - Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
Completed NCT00462488 - Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ Phase 2
Recruiting NCT05621837 - Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
Recruiting NCT05644041 - Intravesical Gemcitabine in Patients With NMIBC Phase 2
Completed NCT04635566 - Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute N/A
Recruiting NCT04861584 - Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects Phase 2
Completed NCT01836978 - Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy N/A
Terminated NCT01374789 - PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer Phase 2
Recruiting NCT03844256 - A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study Phase 1/Phase 2